Spicamycin, a nucleoside antibiotic containing fatty acids with a variety of chain lengths (C12~C18), showed potent antitumor activity against human gastric cancer SC-9 and human breast cancer MX-1in a xenograft model. Wehave madeseveral semi-synthetic spicamycin analogues (SPMs) which differed in the chain length of the fatty acid moiety, and examined their structure-antitumor activity relationship. The cytotoxic activities of SPMsdepended on the chain length of the fatty acid moiety, with dodecanoyl, tetradecanoyl, hexadecanoyl and icosanoyl analogues (SPM VIII, SPM X, SPM XII and SPMXVI) exhibiting the most potent cytotoxic activity against P388 murine leukemia cells.
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SPMVIII showed the most activity against SC-9 in the human tumor xenograft model with the highest therapeutic index among SPMs. The antitumor activity of SPMVIII was superior to that of mitomycin C.
1439 Spicamycin (Fig. 1) , a mixture of several related components that differ only in the nature of their fatty acid moieties produced by Streptomyces alanosinicus 879-MT3, was isolated as a differentiation inducer of HL60and Ml myeloid leukemic cells. It also exhibited antitumor activity against P388 murine leukemia1)2).
Septacidin, a compoundsimilar to spicamycin, was reported to have antitumor activity against several murine tumors3). However, its effect on humantumor xenografts has not been reported yet.
In this study we have examined the antitumor activity of spicamycin against several humantumors using the nude mice humantumor xenograft model4~7).
Weprepared several semi-synthetic spicamycin analogues (SPMs) which differed in the length of the fatty acid moiety and examined their in vitro and in vivo structure-activity relationship in the hope of finding compounds with higher antitumor activity and improved therapeutic effects on human tumor xenografts.
Chemistry
Spicamycin (1) was obtained from the cultured broth of Streptomyces alanosinicus 879-MT3 by the method of Hayakawaet al.2). Modification of the fatty acid moiety of spicamycin was carried out by the methods described by Aszalos et al.3) (Fig. 1) . The amino nucleoside moiety of spicamycin (SAN, 2) was prepared by hydrolysis of spicamycin with 10% HCl -MeOH.Coupling of appropriate fatty acids with glycine yielded acyl-glycines, which were condensed with 2 to afford fatty acid derivatives (SPMs). ine stereochemistry ot 6' position and the absolute configuration have not been determined yet.
Results
Antitumor Activity of Spicamycin against HumanTumors The antitumor activity of spicamycin against 3 humangastric cancers, one humanbreast cancer and one humanlung cancer was tested using a nude mice humantumor xenograft model. The dose used in these experiments was the maximumtolerated dose in each tumor bearing mice (Table I) . The most dramatic effect of spicamycin was apparent in the experiment on SC-9. Spicamycinalso exhibited antitumor activity against MX-1but had no activity against three other tumors.
Cytotoxicity of SAN, SPMsand Spicamycin against P388 Murine Leukemia Cells In Vitro The cytotoxicity of SAN, SPMsand spicamycin against P388 cells is summarized in Table 2 . SAN had no cytotoxic activity. The activities' of SPMshad clear relationship with the length of fatty acid chain. That is, the activities increased with the increase of chain length, reaching a maximumwith the C12 acid of SPMVIII. The activities of SPMVIII, SPMX, SPMXII and SPMXVI appeared to be stronger than that of the parent compound, spicamycin. This result indicates that the fatty acid chain moiety is essential for the cytocidal activity of SPMs, whose potency depends on the length of their fatty acids.
In Vivo Antitumor Activity of SAN, SPMs and Spicamycin against SC-9 HumanGastric Cancer The antitumor activity of SAN, SPMsand spicamycin against SC-9 was evaluated by tumor growth inhibition rate (T.G.I.R.) at each dose and the therapeutic index (T.I.) of each SPMwas calculated (Table  3 ). SANhad no activity or toxicity even at the highest dose. SPMIV and SPMV with short-chain fatty acids (C8 and C9) showed toxicities at doses of more than 12mg/kg/day, but had no antitumor activity. SPM VI, SPM VII, SPM VIII and SPM X which have intermediate-chain fatty acids (C10, Cn, C12 and C14) exhibited inhibitory effects on the growth of SC-9. On the other hand, SPMXII and SPMXVI with long-chain fatty acid moieties (C16 and C20) showed no therapeutic effect but had toxicity. Amongthe active SPMs, SPMVIII showed a considerable reduction of toxicity without loss of the antitumor activity, resulting in the highest T.I. which was 4-times higher than that of spicamycin (Table 3) . Fragments of human tumor were implanted subcutaneously into athymic nude mice. Whenthe tumor size reached 100~300 mm3,spicamycin was given intravenously daily for five days.
a Maximum tumor growth inhibition rate (T.G.I.R.) values through the experimental span were expressed. Bold figures mean that spicamycin was evaluated as "effective" according to the criteria described in "Experimental."~, Carbonnumber TiO , .
Compound offatty acid IC50 (M?/ml) P388 cells were exposed to SAN, spicamycin or SPMs for 3 days and the cell number was counted. Fragments of SC-9 human gastric cancer were implanted subcutaneously into athymic nude mice. Whenthe tumor size reached 100~300mm3, SAN, SPMs or spicamycin were given iv daily for five days. a Therapeutic index (T.I.) = maximumtolerated dose/minimum effective dose b Results were expressed as the values of maximumtumor growth inhibition rate (T.G.I.R.) through the exprimental span; five mice per group. c One or more animals died. d Bold figures mean that SPMsor spicamycin were evaluated as "effective" according to the criteria described in " Experimental".
The growth curves of SC-9 treated with SPM VIII or mitomycin C (MMC)are shown in Fig. 2 . Remarkable remission of the tumor by SPMVIII was observed at the dose of 12mg/kg/day. The minimumrelative tumor volumes (RVs) of each treatment were 0.09 (SPM VIII 12mg/kg/day), 0.2f (SPM VIII 6mg/kg/day), 0.60 (SPM VIII 3 mg/kg, day) and 0.86 (MMC). The effect of SPM VIII ai all three doses in reducing the tumor mass of SC-S was greater than that of MMC.
Discussio n
In this study we found that spicamycin had in vivo antitumor activity against several human tumors, especially high activity was seen against SC-9 human gastric cancer. The structure-antitumor activity relationship indicated that the iV-acylated glycine moiety was essential for SPMs to have antitumor activity because SANshowed no in vitro and in vivo activity. The structure activity study also indicated that there was a certain relationship between the length of the fatty acid chain and antitumor activity or toxicity.
On the whole, both in vitro cytotoxicity and in vivo toxicity increased with an increase in the number of carbons in the fatty acid moiety of SPMs.
However,there were somedisagreements between in vitro cytotoxicity and in vivo toxicity findings. Although the cytotoxicity of SPMIV, SPMV, SPMVI, SPMVII and SPMVIII increased as the number of carbons in the fatty acid moiety increased, almost all these SPMs showed the same toxicity against nude mice. SPMVIII, SPM X, SPM XII and SPMXVI showed similar cytotoxicity but the in vivo toxicity of these compounds increased with an increase in the length of the fatty acid chain. These differences may depend on the difference of SPMsin their selective toxicity against tumor cells in vivo. The fact that SPMVIII showed the maximumT.I. suggests that SPM VIII has the highest specificity towards tumor cells among the SPMs. In addition to spicamycin and septacidin, glidobactins8'9), 13-O-acyl derivatives ofrhizoxin10>1 1) and 7V4-acyl derivatives of l -/?-D-arabinofuranosylcytosine(ara-C)1 2) are knownas antitumor agents which have a fatty acid moiety in their structures. It was reported that their activities depended on the length of their fatty acid chains. Although their modes of action may be different from that of spicamycin, the fatty acid moieties of these compounds may play an important role, possibly in the permeability into the tumor cells.
SPMVIII showed a maximumT.I. amongSPMsand significant tumor remission which surpassed that by MMC. The T.G.LR. value of SPMVIII on day 14 was 98%and this value was superior to those of other well-known antitumor drugs reported by Inaba et al. 13 ). These results prompt us to study SPM VIII in further detail.
Experimental General MP's were determined with a Yanagimotomicro hot-stage apparatus. Specific rotations were obtained with a Jasco DIP-140 spectropolarimeter. IR spectra were recorded on a Jasco A-3 spectrophotometer. UVspectra were recorded on a Hitachi U-3200 in MeOH solution and NMR spectra were recorded on a Jeol GX-500 spectrometer. The FD mass spectra were obtained with a Hitachi M80mass spectrometer.
Spicamycin Amino Nucleoside (2)
A solution of 1.0g of 1 in 100ml of 10% HCl-MeOH was allowed to stir at 30°C for 100 hours. The solution was concentrated in vacuo to the minimumvolume and diethyl ether was added. The resulting precipitate was centrifuged and washed with diethyl ether to give a white powder. This powder was dissolved in water and washed with n-butanol. The aqueous layer was neutralized with silver carbonate and the precipitate formed was filtered off. The filtrate was concentrated and the residue was further purified by column chromatography on silica gel (CHC13 -MeOH, 2 : 1) to give 2 (344mg, 68% yield); MP 180-183°C (decomp.), 13 mol) in NaOH (5.2g, 0.13 mol) aqueous solution (100ml) was added dodecanoyl chloride (2.84g, 0.013mol) and the mixture was stirred for 60 minutes at room temperature. The reaction mixture was adjusted to pH 3 with concHCl. The resulting precipitate was collected and washed with water and diethyl ether to give 3 (3.27 g, 98% yield) as a white pewder.
Other acyl-glycines were prepared by a similar procedure.
/?-Nitrophenyl Ester of Dodecanoylglycine (4; m = 10) To a stirred solution of 3 (3.27g, 0.013mol) in DMFwas added /?-nitorophenol (1.76g, 0.013mol) and JV,JV'-dicyclohexylcarbodiimide (2.62 g, 0.013 mol). After 12 hours, the reaction mixture was filtered. The filtrate was concentrated and recrystallized from ethyl acetate three times to give 4 (4.17 g, 85% yield) as white needles.
Other /?-nitrophenyl esters of acyl-glycine were prepared by a similar procedure. (9) THE JOURNAL OF ANTIBIOTICS SEPT. 1993 To a stirred solution of 2 (500mg, 1.53mmol) in DMFwas added 4 (578mg, 1.53mmol) and Preparation of compounds 5, 6, 7, 8, 10, ll and 12 followed a similar process as discribed above using appropriate fatty acids. In Vitro Cytotoxicity P388 murine leukemia cells were kindly provided by Cancer Chemotherapy Center, Japanese
Foundation for Cancer Research, Tokyo, Japan. Tumorcells were maintained and suspended in RPMI 1640 Medium (Nissui Pharmaceutical Co., Ltd., Tokyo, Japan) supplemented with 10% heat-inactivated fetal calf serum (Gibco Laboratories, Grand Island, NY), 100 units/ml of penicillin (Meiji Seika Kaisha
Ltd., Tokyo, Japan), 100/xg/ml of streptomycin (Meiji Seika Kaisha Ltd., Tokyo, Japan) and 2-mercaptoethanol (5 x 10" 5 m). The cultures were incubated at 37°C in a humidified atmosphere containing 5% CO2. For drug treatment experiments, 5 x 103 tumor cells/well in 96-well plates (U96 Micro Well, Nunc Inter. Med., Roskilde, Denmark) containing 0.1 ml of the growth medium described above were cultured in the graded concentrations of SPMsor spicamycin. After 72 hours incubation, the numberof cells in each well was counted with a Model ZMCoulter Counter (Coulter Electronics Limited, England). Four wells were used for each drug concentration. The IC50 was determined by plotting the logarithm of the drug concentration against the growth rate of the treated cells14).
In Vivo Antitumor Activity For all experiments, 6~8-week-old female, athymic nude mice (BALB/c nu/'nu Sic, Japan SLC Inc., Shizuoka, Japan) were used. The animals were kept under specific pathogen free conditions using laminar air flow racks and were fed sterile food and water ad libitum.
Human gastric cancers SC-7, SC-9 and 4-1ST, human breast cancer MX-1and human lung cancer LX-1 were kindly supplied by the Central Institute for Experimental Animals, Kanagawa, Japan, and maintained in athymic nude mice. Chemotherapeutic experiments were performed as described by Inaba et al. 13 ). Fragments of xenografts were implanted sc into the right subaxillary region of athymic nude mice. Whenthe tumors had grown to a palpable size (100~300mm3), the mice were randomly allocated to several experimental groups consisting of five animals each and SPMsor spicamycin at each dose were given intravenously by daily injection for five days. MMCpurchased from Kyowa Hakko Kogyo Co., Tokyo, Japan, was given intravenously only on day 1. Control mice were given 10jwl/g vehicle. From the start of the injections, the tumor volume (V) was calculated once or twice a week for 3 weeks as follows; V=abc/2, where a and b are the long and short diameter and c is the height of the tumor mass in mm. Relative tumor volume (RV) is expressed as RV=Vn/V0,where Vn is the tumor volume on day n and Vo is the initial tumor volume at the time treatment was commenced(day 1). T.G.I.R. was determined as follows; T.G.I.R.=(1 -T/C) x 100 where T is the mean of RVin treated mice and C is the mean of RV in control mice.
Evaluation as "effective" was based on the maximumT.G.I.R. (%) for an experimental span of 50% or more showing statistical significance as determined by the Mann-Whitney's U-test (P < 0.05, one sided). A toxic dose was defined as one causing the death of one or more mice in a group. The therapeutic index (T.I.) was determined as follows; T.I. = maximumtolerated dose/minimum effective dose.
